Quan Anh Vu
Geen lopende functies
Vermogen: 272 258 $ op 31-03-2024
Profiel
Quan Anh Vu formerly worked at Baleena Bioscience, Inc., as Chief Executive Officer in 2021, Solganick & Co., Inc., as Managing Director from 2019 to 2021, Opiant Pharmaceuticals, Inc., as Vice President from 2016 to 2019, Ocugen, Inc., as Chief Financial, Accounting & Business Officer in 2023, and 180 Life Sciences Corp., as Chief Operating & Business Officer from 2021 to 2023.
Mr. Vu received his undergraduate degree from the University of California, Los Angeles.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
OCUGEN INC
0.06% | 06-03-2023 | 165 934 ( 0.06% ) | 272 132 $ | 31-03-2024 |
180 LIFE SCIENCES CORP.
0.01% | 18-12-2023 | 54 ( 0.01% ) | 126 $ | 31-03-2024 |
Eerdere bekende functies van Quan Anh Vu
| Bedrijven | Functie | Einde |
|---|---|---|
| OCUGEN, INC. | Director of Finance/CFO | 14-08-2023 |
| 180 LIFE SCIENCES CORP. | Chief Operating Officer | 18-01-2023 |
| Solganick & Co., Inc. | Corporate Officer/Principal | 01-10-2021 |
| Baleena Bioscience, Inc. | Corporate Officer/Principal | 01-10-2021 |
| OPIANT PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01-08-2019 |
Opleiding van Quan Anh Vu
| University of California, Los Angeles | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| OCUGEN, INC. | Health Technology |
| 180 LIFE SCIENCES CORP. | Health Technology |
| Bedrijven in privébezit | 3 |
|---|---|
Opiant Pharmaceuticals, Inc.
 Opiant Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Opiant Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development of pharmaceutical solutions for common addictions and related disorders. The firm focuses on developing treatment to reverse opioid overdoses, treatment for overweight and obese patients with binge eating disorder and treatment for patients with Bulimia Nervosa. Its principal product Naloxone is a medicine which is available through injection can reverse the overdose of prescription and illicit opioids. The company was founded on June 21, 2005 and is headquartered in Richmond, VA. | Health Technology |
| Solganick & Co., Inc. | Finance |
| Baleena Bioscience, Inc. |
